Cyndeo Wealth Partners LLC Buys 2,329 Shares of Johnson & Johnson (NYSE:JNJ)

Cyndeo Wealth Partners LLC grew its stake in shares of Johnson & Johnson (NYSE:JNJ) by 3.9% during the fourth quarter, Holdings Channel reports. The institutional investor owned 62,185 shares of the company’s stock after buying an additional 2,329 shares during the period. Cyndeo Wealth Partners LLC’s holdings in Johnson & Johnson were worth $8,993,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently made changes to their positions in JNJ. IFS Advisors LLC grew its position in shares of Johnson & Johnson by 138.9% during the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after purchasing an additional 100 shares in the last quarter. Highline Wealth Partners LLC purchased a new stake in Johnson & Johnson during the 3rd quarter valued at approximately $31,000. RPg Family Wealth Advisory LLC bought a new stake in shares of Johnson & Johnson during the third quarter valued at approximately $35,000. Mowery & Schoenfeld Wealth Management LLC lifted its holdings in shares of Johnson & Johnson by 58.7% in the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock worth $40,000 after buying an additional 91 shares in the last quarter. Finally, Activest Wealth Management purchased a new position in Johnson & Johnson during the third quarter valued at $40,000. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Stock Up 4.1 %

Shares of JNJ opened at $152.91 on Tuesday. The firm has a fifty day moving average price of $147.85 and a 200-day moving average price of $156.10. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. The firm has a market capitalization of $368.15 billion, a P/E ratio of 22.99, a P/E/G ratio of 2.45 and a beta of 0.51. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $168.85.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. The business had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22,438,500 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The company’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.29 EPS. Equities research analysts expect that Johnson & Johnson will post 10.56 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.24%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s payout ratio is 74.59%.

Wall Street Analysts Forecast Growth

Several research firms have commented on JNJ. Wells Fargo & Company dropped their price objective on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a report on Thursday, January 23rd. Citigroup cut their price target on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a report on Wednesday, December 11th. Barclays decreased their price objective on Johnson & Johnson from $160.00 to $159.00 and set an “equal weight” rating on the stock in a report on Tuesday, January 21st. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Finally, Morgan Stanley lowered their price objective on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a research report on Thursday, January 23rd. Nine analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and an average target price of $170.06.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger acquired 1,000 shares of the company’s stock in a transaction dated Thursday, December 12th. The shares were purchased at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the purchase, the director now owns 1,000 shares in the company, valued at approximately $147,220. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.